T1	Participants 0 193	Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403
T2	Participants 330 396	experienced, human immunodeficiency virus (HIV)-infected children.
T3	Participants 643 770	Forty-one children and youths between 5 months and 21 years with prior NRTI and no prior NNRTI or protease inhibitor experience
